Quality of life in heart failure patients may be improved with Canagliflozin category

Published On 2021-12-05 06:00 GMT   |   Update On 2021-12-05 06:00 GMT

The CHIEF- HF trial results have shown that treating heart failure (HF) patients with canagliflozin a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly improves quality of life. Canagliflozin is currently approved for glycemic control in patients with type 2 diabetes. It is also approved for the treatment of diabetic kidney disease and to reduce the risk of HF hospitalizations...

Login or Register to read the full article

The CHIEF- HF trial results have shown that treating heart failure (HF) patients with canagliflozin a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly improves quality of life. Canagliflozin is currently approved for glycemic control in patients with type 2 diabetes.

It is also approved for the treatment of diabetic kidney disease and to reduce the risk of HF hospitalizations in patients with type 2 diabetes. It also gained an indication for the reduction of major adverse cardiovascular events in patients with type 2 diabetes and an increased risk of atherosclerotic cardiovascular disease.


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News